Medical Advocates
HAART/ART
  Hepatic Adverse Events
General Reports
 Hepatic Failure       
Hepatotoxicity
Hyperbilirubinemia              
Fatty Liver





 		  
HAART Adverse Events                         Main New/Newsworthy  Home Page
Last Update:  April 20, 2012  
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       
          Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
 HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.
 Neuman MG, Schneider M, Nanau RM, Parry C.
Int J Hepatol. 2012;2012:760706.
Paper

Influence of antiretroviral therapy on liver disease.
Kovari H, Weber R.
 Curr Opin HIV AIDS. 2011 Apr 20
 Abstract

Clinical syndromes and consequences of antiretroviral-related hepatotoxicity.
Núñez M.
Hepatology. 2010 Sep;52(3):1143-55.
 Abstract

The nephrotoxic effects of HAART.
Izzedine H, Harris M, Perazella MA.
Nat Rev Nephrol. 2009 Oct;5(10):563-73
 Abstract

FULL-TEXT ARTICLE
 Is Antiretroviral Therapy Causing Long-Term Liver Damage? A Comparative Analysis of
HIV-Mono-Infected and HIV/Hepatitis C Co-Infected Cohorts.
Moodie EE, Pant Pai N, Klein MB.
PLoS ONE. 2009;4(2):e4517.
Paper
 
HAART and Liver: A discussion of hepatic disease in those living with HIV.
Cooper C, Adams PC.
 Can J Gastroenterol. 2008 Dec;22(12):973-5.
 Abstract
 
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1
mono-infected patients on antiretroviral therapy.
Ingiliz P, Valantin MA, Duvivier C, et al
 Hepatology. 2008 Dec 10.
Abstract
 
Hepatic histopathology and clinical characteristics associated with antiretroviral therapy
in HIV patients without viral hepatitis.
Akhtar MA, Mathieson K, Arey B, et al
Eur J Gastroenterol Hepatol. 2008 Dec;20(12):1194-204
 Abstract
 
Highly active antiretroviral therapy-induced liver injury.
Inductivo-Yu I, Bonacini M.
Curr Drug Saf. 2008 Jan;3(1):4-13.
Abstract
 
Liver Enzymes Elevation and Immune Reconstitution Among Treatment-Naïve
HIV-Infected Patients Instituting Antiretroviral Therapy.
Ofotokun I, Smithson SE, Lu C, et al 
Am J Med Sci. 2007 Nov;334(5):334-341
 Abstract

Drug-Induced Liver Injury Associated with HIV Medications.
Jain MK. 
Clin Liver Dis. 2007 Aug;11(3):615-39.
 Abstract

     Conference Reports, Abstracts, and Posters

  Evaluation of liver damage in HIV-1-positive patients on antiretroviral therapy with
chronic transaminases elevation of unknown origin (The HEALTH study)
Valantin M.-A., Ingiliz P., Charlotte F, et al
 (4th IAS Conference)
 Abstract
Hepatic Failure
       

          Journal Papers, Abstracts, and Commentaries

 
Orthotopic liver transplantation in patients with human immunodeficiency virus and
end-stagel iver disease.
Neff GW, Bonham A, Tzakis AG
 Liver Transpl 2003 Mar;9(3):239-47
 Abstract
 
Acute hepatic failure and lactate acidosis associated with antiretroviral treatment
or HIV.
Koch RO, Graziadei IW, Zangerle R, et al 
Wien Klin Wochenschr 2003 Feb 28;115(3-4):135-40
 Abstract
Hepatotoxicity 
       
          Journal Papers, Abstracts, and Commentaries
 
 
Liver Toxicity of Antiretroviral Combinations Including Fosamprenavir Plus Ritonavir 1400/100 mg
Once Daily in HIV/Hepatitis C Virus-Coinfected Patients.
Merchante N, López-Cortés LF, Delgado-Fernández M,  et al
AIDS Patient Care STDS. 2011 Jun 20.
Abstract

Hepatotoxicity of antiretroviral drugs.
Abrescia N, D'Abbraccio M, Figoni M, et al 
Curr Pharm Des. 2005;11(28):3697-710
Abstract

Antiretroviral-associated Hepatotoxicity.
 Kress KD.   
Curr Infect Dis Rep. 2005 Mar;7(2):103-107.
 Abstract
 
Hepatotoxicity of antiretrovirals : incidence, mechanisms and management.
 Nunez M, Soriano V  
Drug Saf. 2005;28(1):53-66
 Abstract

Severe hepatotoxicity during combination antiretroviral treatment: incidence,
liver histology, and outcome.
Puoti M, Torti C, Ripamonti D, et al
 J Acquir Immune Defic Syndr 2003 Mar 1;32(3):259-67
 Abstract

Looking beyond highly active antiretroviral therapy: drug-related hepatotoxicity
in patients with human immunodeficiency virus infection.
Orenstein R, Tsogas N.
Pharmacotherapy 2002 Nov;22(11):1468-78
Abstract

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral
combination therapy.
Wit FW, Weverling GJ, Weel J, et al
J Infect Dis 2002 Jul 1;186(1):23-31
 Abstract

Hepatotoxicity associated with antiretroviral therapy containing dual versus single
protease inhibitors in individuals coinfected with hepatitis C virus and human
immunodeficiency virus.
Cooper CL, Parbhakar MA, Angel JB.
Clin Infect Dis 2002 May 1;34(9):1259-63
 Abstract

Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases.
Clark SJ, Creighton S, Portmann B, et al.
J Hepatol 2002 Feb;36(2):295-301
 Abstract

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic
disorders in human immunodeficiency virus-infected patients.
Chene G, Angelini E, Cotte L, et al.
Clin Infect Dis 2002 Mar 1;34(5):649-57
 Abstract

Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy
Lana R, Nunez M, Mendoza JL, Soriano V.
 Med Clin (Barc) 2001 Nov 17;117(16):607-10
 Abstract
 

  
     Conference Reports, Abstracts, and Posters
 
  POSTER
 Side Effects of HAART in HIV-1-infected Pregnant and Non-pregnant Women:
Pregnancy Is Associated with Hepatotoxicity, while Ethnicity Is Associated with Rash
 I Snijdewind, C Smit, M Godfried, et al
 (16 CROI)
 PDF Poster     Abstract
Hyperbilirubinemia
       

          Journal Papers, Abstracts, and Commentaries

  Hyperbilirubinemia in the setting of antiviral therapy.
 Korenblat KM, Berk PD.  
Clin Gastroenterol Hepatol. 2005 Apr;3(4):303-10.
 Abstract
Fatty Liver
       

          Journal Papers, Abstracts, and Commentaries
 
  Increased fat accumulation in the liver in HIV-infected patients with antiretroviral
therapy-associated lipodystrophy.
Sutinen J, Hakkinen AM, Westerbacka J,
AIDS 2002 Nov 8;16(16):2183-93
 Abstract		  

HAART Adverse Events Main New/Newsworthy  Home Page

HAART/ART Hepatic Adverse Events